Answers are grounded in this paper and cite their sources.
Arsenic is a widespread environmental carcinogen whose genotoxicity is commonly attributed to oxidative DNA damage and replication-associated lesions. Here, we identify RNA polymerase II (RNAPII) as an important determinant of early arsenic-induced DNA damage checkpoint signaling. In budding yeast, acute As(III) exposure induced rapid, chromosomewide γH2A accumulation under low oxidative stress, without requiring ongoing bulk DNA replication or causing detectable chromosome fragmentation. Unexpectedly, depletion of Rpb1, the largest subunit of RNAPII and a key component of its catalytic center, markedly attenuated this response. Comparison of different transcriptional perturbations revealed that only selected disruptions of RNAPII function, including Rpb1 inactivation in the rpb1-1 mutant, induced widespread γH2A accumulation. These contrasting effects suggest that checkpoint activation depends on the presence and particular functional states of RNAPII. Consistent with its involvement, As(III) reduced RNAPII chromatin occupancy and Rpb1 abundance, while arsenic-affinity assays recovered the RNAPII complex. However, As(III) did not measurably inhibit RNA elongation by purified RNAPII in vitro. In human cells, acute As(III) exposure induced ATR phosphorylation and γH2AX accumulation under low-ROS conditions, while pharmacological inhibition of transcription also triggered γH2AX phosphorylation. Together, our findings establish an important contribution of RNAPII to early arsenic-induced checkpoint signaling and suggest that the transcription machinery can couple environmental stress to a chromosome-wide DNA damage response.
No takes yet. Share an insight, caveat, or question.
NAWROT et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: